For Biosimilar Savings In Medicaid, CMS Pushes Supplemental Rebates, Prescriber Outreach
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS notifies states that their Medicaid programs should consider using preferred drug lists and supplemental drug rebates from manufacturers, as well as prescriber education programs to maximize use of biosimilar products.